Fighting Blindness Canada Continues to Call for Coverage of Sight-Saving Treatment after Ontario Becomes Fourth Province to Sign Agreement
Fighting Blindness Canada is pleased to hear Ontario has approved public coverage of Luxturna® (generic name: voretigene neparvovec-rzyl) . This gene therapy treatment slows and may even restore some vision loss due…
Advances in Stem Cell Therapy made by FBC-Funded Researcher
Cells Grown in Lab can Reach Out and Connect to Other Retina Cells Fighting Blindness Canada (FBC) funded scientist Dr. David Gamm (University of Wisconsin) has successfully shown that photoreceptor cells grown…
top 10 articles that Captured Your Attention in 2022!
Funding innovative vision research is at the heart of Fighting Blindness Canada (FBC). Throughout the year, our monthly e-newsletter has shared articles and publications showcasing the amazing research and advocacy work taking…
FBC Says A Fond Farewell and Thank You to Doug Earle
After nearly four years at the helm of Fighting Blindness Canada (FBC), Doug Earle has stepped down as President and CEO. Doug came to FBC with 30 years of fundraising experience under…
Their parents thought they were afraid of the dark. Then these twins learned the truth — and the fight to save their sight began
Nathan and Andre needed a game-changing gene-specific therapy. But the costs were astronomical and the parents were at a loss. Here’s how I witnessed their story go from tragic to triumphant. Twins…
NAC Attack: A Phase III clinical trial to test an oral therapy for retinitis pigmentosa
Starting in 2023, a new clinical trial called NAC Attack will be launched to test an oral medication, N-acetylcysteine (NAC), as a potential therapy for patients with retinitis pigmentosa (RP). NAC Attack…
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.